Novartis Hopes Lubris In-Licensing Deal Will Lead To Dry Eye Solution
Executive Summary
ON the lookout for potential ophthalmology options despite recent setbacks in the area, Novartis has now spotted ECF843, an investigative recombinant human lubricin – or natural lubricant – for dry eye.
You may also be interested in...
Novartis CEO Touts R&D 'Wild Cards' As Proof Of Deep Pipeline
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
Start-Up Quarterly Statistics: Private And Public Firms Were Prolific Fundraisers
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.